Search results
Showing 1 to 50 of 2008 results for news
Home News Articles...
Home News...
Keeping you up-to-date with our worldwide collaborations, opportunities and developments - the NICE International newsletter
Keeping those working within the life sciences sector up-to-date with important developments.
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
Keeping you up-to-date with important developments.
Lipid disorders: FH assessment and diagnosis (new readings) (IND261)
This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245
Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
This indicator covers the percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM09
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
Healthcare-associated infections: prevention and control in primary and community care (CG139)
This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)
This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
View recommendations for NG47Show all sections
NICE appoints Dr Adrian Hayter as its new chief medical officer
Dr Adrian Hayter joins NICE from the Royal College of General Practitioners bringing more than three decades of frontline clinical and national leadership experience to the role.
New take at home drug recommended for people with chronic lymphocytic leukaemia
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
Tools for building or evaluating a medtech evidence base with NICE
Have your say on NICE's adoption of the new EQ-5D-5L value set
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
Home News Blogs...
Hypothermia: prevention and management in adults having surgery (CG65)
This guideline covers preventing and managing inadvertent hypothermia in people aged 18 and over having surgery. It offers advice on assessing patients’ risk of hypothermia, measuring and monitoring temperature, and devices for keeping patients warm before, during and after surgery.
This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.
New life-extending treatment given the green light for people with rare form of bile duct cancer
A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.
Improving outcomes in children and young people with cancer (CSG7)
This guideline covers how healthcare services for children and young people with cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
Improving outcomes for people with brain and other central nervous system tumours (CSG10)
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This quality standard covers the care of adults (aged 18 and over) with suspected or confirmed acute heart failure. It describes high-quality care in priority areas for improvement.
View quality statements for QS103Show all sections
Sections for QS103
- Quality statements
- Quality statement 1: Single measurement of natriuretic peptide
- Quality statement 2: Transthoracic doppler 2D echocardiography
- Quality statement 3: Organisation of care – early specialist input
- Quality statement 4: Starting or continuing beta-blocker treatment
- Quality statement 5: Drug therapy
- Quality statement 6: Follow-up clinical assessment
- About this quality standard
This quality standard covers the management of colorectal (bowel) cancer in adults. It includes managing local disease and secondary tumours (metastatic disease). It describes high-quality care in priority areas for improvement.
View quality statements for QS20Show all sections
Sections for QS20
- Quality statements
- Quality statement 1: Testing for Lynch syndrome
- Quality statement 2: Discussion about treatment options for early rectal cancer
- Quality statement 3: Testing to guide systemic anti-cancer treatment
- Quality statement 4: Follow-up for detecting local recurrence and distant metastases
- Update information
- About this quality standard
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
Digital technologies to support self-management of asthma: early value assessment
In development Reference number: GID-HTE10063 Expected publication date: 05 May 2026
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.
This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS97Show all sections
Sections for QS97
- Quality statements
- Quality statement 1: Documentation using the structured assessment guide
- Quality statement 2: Advice about carrying personal structured drug information
- Quality statement 3: Referral to specialist drug allergy services
- Quality statement 4: Recording drug allergy status in electronic medical records
- Quality statement 5: Updating information on drug allergy status
- Quality statement 6 (developmental): Prescription information on drug avoidance
- About this quality standard
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
Awaiting development Reference number: GID-TA11840 Expected publication date: TBC
NICE priority methodological research areas.
NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments. This follows the government’s decision to increase the thresholds that NICE can use in technology appraisals to £25,000 to £35,000 per quality-adjusted life year gained.
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased...
Healthcare-associated infections: prevention and control (PH36)
This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.
Show all sections
Sections for PH36
- Overview
- Introduction
- Quality improvement statement 1: Board-level leadership to prevent HCAIs
- Quality improvement statement 2: Be a learning organisation
- Quality improvement statement 3: HCAI surveillance
- Quality improvement statement 4: Workforce capacity and capability
- Quality improvement statement 5: Environmental cleanliness
- Quality improvement statement 6: Multi-agency working to reduce HCAIs
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
Polycystic ovary syndrome: diagnosis and management Development of new guideline ongoing Postnatal care - Pregnancy and complex social
This quality standard covers the safe and effective use of medicines. It covers people of all ages who are taking medicines, including those who are not getting the full benefit from their medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS120Show all sections
Sections for QS120
- Quality statements
- Quality statement 1: Shared decision-making
- Quality statement 2: Patient involvement in reporting medicines-related patient safety incidents
- Quality statement 3: Learning from medicines-related patient safety incidents
- Quality statement 4: Medicines reconciliation in acute settings
- Quality statement 5: Medicines reconciliation in primary care
- Quality statement 6: Structured medication review
- About this quality standard
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.
This quality standard covers diagnosing and managing hypertension (high blood pressure) and pre-eclampsia during pregnancy, labour and birth. It also covers advice for women with hypertension who may become pregnant and postnatal care for women who have had hypertension or pre-eclampsia. It describes high-quality care in priority areas for improvement.
View quality statements for QS35Show all sections
Sections for QS35
- Quality statements
- Quality statement 1: Pre-pregnancy advice for women with treated hypertension
- Quality statement 2: Antenatal assessment of pre-eclampsia risk
- Quality statement 3: Antenatal blood pressure targets
- Quality statement 4: Assessing women with severe hypertension in pregnancy
- Quality statement 5: Admission to hospital for women with pre-eclampsia
- Quality statement 6: Timing of birth for women with pre-eclampsia
- Quality statement 7: Transfer of information about ongoing management